ReviewDermatology and therapy2025
Acne Conglobata: Understanding This Rare Form of Acne and Management Strategies.
Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mid-childhood acne conglobata successfully treated with adalimumab.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne conglobata is a severe, often eruptive, form of acne included in the follicular occlusion tetrad along with hidradenitis suppurativa, pilonidal cysts, and dissecting cellulitis of the scalp. The pathogenesis is complex and likely multifactorial with contribution from both extrinsic and intrinsic factors. Studies have shown a slight male predominance. Acne conglobata is clinically characterized by large, purulent nodules and abscesses, coalescing into large masses or plaques. It is often recalcitrant to common acne therapies, making management difficult for clinicians. Isotretinoin is considered the first-line therapy but must be started at a conservative dosage as it can paradoxically worsen flares. Biologic agents, such as tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitors, along with photodynamic therapy (PDT) and carbon dioxide (CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.